miR-146a inhibits ovarian tumor growth in vivo via targeting immunosuppressive neutrophils and enhancing CD8+ T cell infiltration
Immunotherapies have emerged as promising strategies for cancer treatment. However, existing immunotherapies have poor activity in high-grade serous ovarian cancer (HGSC) due to the immunosuppressive tumor microenvironment and the associated low tumoral CD8+ T cell (CTL) infiltration. Through multip...
Main Authors: | Rui Chen, Elaina Coleborn, Chintan Bhavsar, Yue Wang, Louisa Alim, Andrew N. Wilkinson, Michelle A. Tran, Gowri Irgam, Sharat Atluri, Kiefer Wong, Jae-Jun Shim, Siddharth Adityan, Ju-Seog Lee, Willem W. Overwijk, Raymond Steptoe, Da Yang, Sherry Y. Wu |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-12-01
|
Series: | Molecular Therapy: Oncolytics |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2372770523000700 |
Similar Items
-
A nanotherapeutic strategy that engages cytotoxic and immunosuppressive activities for the treatment of cancer recurrence following organ transplantationResearch in context
by: Zhentao Yang, et al.
Published: (2023-06-01) -
Metastatic Breast Cancer: Review of Emerging Nanotherapeutics
by: Ranga Dissanayake, et al.
Published: (2023-05-01) -
Nanotherapeutics Plus Immunotherapy in Oncology: Who Brings What to the Table?
by: Elise Timon-David, et al.
Published: (2022-10-01) -
Regulating Cholesterol in Tumorigenesis: A Novel Paradigm for Tumor Nanotherapeutics
by: Wu H, et al.
Published: (2024-02-01) -
Theranostic Cancer Treatment Using Lentinan-Coated Selenium Nanoparticles and Label-Free CEST MRI
by: Guanfu Liu, et al.
Published: (2022-12-01)